PF-AtlasКлинические испытания › NCT03473314

Prolonged-Use of Inhaled Gaseous Nitric Oxide for Adult With Non-Tuberculous Mycobacteria Infection

Nitric Oxide gas at 160ppm · Фаза 2

ID реестра
NCT03473314
Фаза
Фаза 2
Статус
Завершено
Препарат / вмешательство
Nitric Oxide gas at 160ppm
Спонсор
University of British Columbia
Начало
2018-03-09
Набор участников
1
Центры
1

Об исследовании

An open labeled Study (NCT03331445) is demonstrating encouraging safety and efficacy results for most subjects receiving 160ppm nitric oxide gas (gNO) for treatment of non-tuberculous mycobacteria (NTM) over a 15 day treatment regimen. In one subject, who had a reduction in sputum culture concentration of Bacterium bolletii from plus 3 to plus 1 corresponding to a 2-3 log10 cfu/gm reduction during the treatment, the one-week post treatment follow-up sputum culture had increased to plus 2. It is hypothesized that a longer treatment period may be necessary to fully eradicate NTM from the sputum culture in chronic lung disease. This study will extend the period of gNO exposure for a prolonged period of time (3 months) to attempt to fully eradicate the NTM in this single subject. This study will transition from the medical clinic to supervised delivery in the patient's home environment.

Открыть NCT03473314 на ClinicalTrials.gov →

Связанные материалы

Медицинская оговорка. Эта страница обобщает публичные данные исследования NCT03473314 только для информации. Это не медицинская рекомендация, не одобрение и не предложение участия. Проверяйте детали на ClinicalTrials.gov и у квалифицированного врача.